American Century Companies Inc. Sells 58,788 Shares of Arvinas, Inc. (NASDAQ:ARVN)

American Century Companies Inc. reduced its stake in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 18.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 252,685 shares of the company's stock after selling 58,788 shares during the quarter. American Century Companies Inc. owned approximately 0.37% of Arvinas worth $4,844,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. KBC Group NV lifted its stake in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after buying an additional 1,255 shares during the last quarter. Quantbot Technologies LP raised its holdings in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock worth $108,000 after acquiring an additional 2,601 shares during the period. Teacher Retirement System of Texas lifted its position in Arvinas by 19.0% during the 4th quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company's stock worth $274,000 after acquiring an additional 2,280 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Arvinas by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company's stock valued at $279,000 after acquiring an additional 1,367 shares during the period. Finally, Handelsbanken Fonder AB boosted its holdings in Arvinas by 16.9% during the fourth quarter. Handelsbanken Fonder AB now owns 22,825 shares of the company's stock valued at $438,000 after acquiring an additional 3,300 shares during the period. Institutional investors own 95.19% of the company's stock.

Arvinas Stock Performance

Shares of NASDAQ ARVN traded down $0.11 during midday trading on Thursday, reaching $6.62. 2,271,611 shares of the company traded hands, compared to its average volume of 1,078,795. Arvinas, Inc. has a 12 month low of $5.94 and a 12 month high of $39.34. The stock's 50-day simple moving average is $12.80 and its 200-day simple moving average is $19.30. The firm has a market cap of $455.27 million, a PE ratio of -2.39 and a beta of 2.30.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter in the prior year, the company posted ($2.53) earnings per share. On average, equities research analysts expect that Arvinas, Inc. will post -3.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Bank of America cut their price objective on Arvinas from $54.00 to $28.00 and set a "buy" rating for the company in a research report on Wednesday, March 12th. BMO Capital Markets set a $20.00 price objective on Arvinas and gave the company an "outperform" rating in a research report on Wednesday, March 12th. Wedbush downgraded shares of Arvinas from an "outperform" rating to a "neutral" rating and lowered their price objective for the stock from $57.00 to $12.00 in a research note on Wednesday, March 12th. Oppenheimer cut shares of Arvinas from an "outperform" rating to a "market perform" rating in a research note on Tuesday, March 11th. Finally, The Goldman Sachs Group lowered shares of Arvinas from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $70.00 to $15.00 in a research report on Thursday, March 13th. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, Arvinas presently has an average rating of "Moderate Buy" and an average price target of $34.53.

Insider Activity

In other news, CEO John G. Houston sold 31,338 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the sale, the chief executive officer now owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. This represents a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Noah Berkowitz sold 8,658 shares of Arvinas stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the transaction, the insider now directly owns 110,023 shares of the company's stock, valued at $945,097.57. This represents a 7.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,230 shares of company stock worth $769,402. Insiders own 5.23% of the company's stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.